1. Introduction {#s0005}
===============

Gaucher disease (GD) is a rare inherited condition. It is caused by bi-allelic variants in the *GBA* gene, which encodes acid β-glucosidase, also referred to as glucocerebrosidase. Reduced activity of this enzyme in GD patients result in lysosomal accumulation of its substrate glucosylceramide in macrophages. As Gaucher cells, these abnormal macrophages enter the liver, spleen, bone marrow and other organs. The presence of Gaucher cells eventually triggers a wide range of phenotypes including the cardinal symptoms hepato- and/or splenomegaly, bone pain and destruction, and highly abnormal blood profiles; a subset of patients also develops neurological symptoms \[[@bb0005]\]. Many Gaucher patients are initially monosymptomatic. Due to non-specificity, individual symptoms occurring in isolation are usually not considered to be an indication of a genetic disorder, let alone interpreted as GD. Age at onset and severity of the disease are highly variable and partially depend on the genotype \[[@bb0005]\]. Together with a lack of awareness due to the condition\'s rarity, the above factors entail a long diagnostic delay in many patients. Determination of glucocerebrosidase enzymatic activity represents a screening tool that can guide diagnosis \[[@bb0010]\]. The sphingolipid Lyso-Gb1, an alternative glucocerebroside degradation product, has recently been introduced as an additional diagnostic biomarker \[[@bb0015]\]. Due to its dynamic nature, it may also provide an objective means for determining disease severity, and for monitoring disease progression as well as therapeutic success \[[@bb0020]\].

We present a family, in which the presence of hepatomegaly and/or splenomegaly in all family members over two generations initially suggested a non-genetic etiology. However, biochemical and genetic follow up revealed an unusual constellation of three pathogenic *GBA* haplotypes combined into four distinct genotypes, thereby resulting in variably severe manifestation of GD.

2. Patients and methods {#s0010}
=======================

All family members are of Caucasian ethnicity. Following a long odyssey in search for a diagnosis, they were eventually referred to the University Hospital Center 'Mother Teresa' in Tirana, which is the only GD center in Albania. All biochemical and genetic tests utilized dried blood spot samples (CentoCard®, CENTOGENE AG, Germany); enzymatic testing of glucocerebrosidase activity was based on standard diagnostic procedures. Lyso-Gb1 was quantified by mass-spectrometry as described previously \[[@bb0015]\]. The *GBA* gene was analyzed using a three-step next generation sequencing (NGS) approach: a primary long range PCR first amplified the gene (but not its closely homologous pseudogene). Ordinary PCRs then generated secondary exon-specific products, which were eventually sequenced in an in-house multiplex NGS setting. Description of variants follows the recommendation of the Human Genome Variation Society \[[@bb0025]\]; historical nomenclature is provided upon first mention.

3. Results {#s0015}
==========

3.1. Clinical presentation {#s0020}
--------------------------

There were a total of seven patients: four in generation I and three in generation II ([Fig. 1](#f0005){ref-type="fig"}A, [Table 1](#t0005){ref-type="table"}). Two of the three siblings in generation II presented with only splenomegaly, while their oldest brother additionally showed bone pain and thrombocytopenia. Slight hip dysplasia and a shorter right leg in II-1 are probably also part of the GD phenotype. All three siblings in generation I had presented with severe hepatosplenomegaly that led to splenectomy in their early 20\'s. In addition, they all reported bone pain and show thrombocytopenia. Bone pain was particularly severe in I-2, who also suffered from epistaxis. I-4 showed only mild hepatosplenomegaly. Following an eventual diagnosis of GD type 1, all patients except for I-4 now receive enzyme replacement therapy (*velaglucerase alfa* (VPRIV®); Shire, Lexington, MA). Of note, the father of generation I, who is an obligate carrier of either c.259C \> T or c.\[1265_1319del;1342G \> C\], reportedly shows signs of Parkinsonism.Fig. 1Family structure and genetic findings. (A) Generation I consists of three affected siblings and one affected spouse, all three offspring in generation II are affected, too. *GBA* genotypes as eventually detected are indicated below the individuals\' symbols (compare [Fig. 1](#f0005){ref-type="fig"}B). (B) Exemplary Sanger sequencing image for each variant (in heterozygosity).Fig. 1Table 1Summary of the clinical and genetic findings.Table 1Patient (compare [Fig. 1](#f0005){ref-type="fig"}A)I-1I-2I-3I-4II-1II-2II-3GenderMaleFemaleMaleFemaleMaleMaleFemaleAge at last examination \[yrs\]4441394318158Clinical findingsSplenomegalyYesYesYesYesYesYesYes (mild)HepatomegalyYesYesYesYesYes----ThrombocytopeniaYesYesYes--Yes----Bone painYesYesyes (severe)--Yes----Additional----epistaxis--short right leg----Overall severitySevereSevereSevereMildSevereMildMild*GBA* genotypeAllele 1c.259C \> Tc.259C \> Tc.259C \> Tc.1226A \> Gc.1226A \> Gc.259C \> Tc.259C \> TAllele 2c.\[1265_1319del; c.1342G \> C\]c.\[1265_1319del; c.1342G \> C\]c.\[1265_1319del; c.1342G \> C\]c.1226A \> Gc.\[1265_1319del; c.1342G \> C\]c.1226A \> Gc.1226A \> GConsequences at protein levelFrom allele 1p.Arg87Trpp.Arg87Trpp.Arg87Trpp.Asn409Serp.Asn409Serp.Arg87Trpp.Arg87TrpFrom allele 2p.Leu422Profs\*4p.Leu422Pfros\*4p.Leu422Profs\*4p.Asn409Serp.Leu422Profs\*4p.Asn409Serp.Asn409SerLyso-Gb1 \[ng/μl\]264109059064.211549.676.3Currently under enzyme replacement therapyYesYesYesNoYesYesYes

3.2. Biochemical findings {#s0025}
-------------------------

The enzymatic activity of glucocerebrosidase was below the lower limit of quantification in II-2 and II-3, and was thereby pathologically decreased. Subsequent measurement of plasma concentrations of Lyso-Gb1 in all seven family members revealed pathologic values above the cutoff of 10 ng/μl. Values \>100 ng/μl were observed in the three siblings of generation I as well as in II-1, while the other three individuals showed more moderate values around 50--80 ng/μl ([Table 1](#t0005){ref-type="table"}).

3.3. Genetic findings {#s0030}
---------------------

Sequencing of the *GBA* gene in the three siblings of generation I disclosed the same three heterozygous variants in each: c.259C \> T (p.Arg87Trp; "R48W" according to historical nomenclature), c.1265_1319del (p.Leu422Profs\*4; "55 bp deletion in exon 9") and c.1342G \> C (p.Asp448His; "D409H"). The spouse of I-3 was found to carry c.1226A \> G (p.Asn409Ser; "N370S") in homozygosity. Accordingly, c.1226A \> G was present in heterozygosity in all three offspring. It was associated with c.1265_1319del and c.1342G \> C in II-1, but with c.259C \> T in II-2 and II-3 ([Fig. 1](#f0005){ref-type="fig"}B). Collectively, these observation enabled the definition of three pathogenic haplotypes: c.259C \> T, c.\[1265_1319del;1342G \> C\] and c.1226A \> G. These are all present in generation I, and were found to be differentially re-assembled in generation II. As a consequence, there are a total of four distinct pathogenic genotypes in the family (compare [Fig. 1](#f0005){ref-type="fig"}A).

4. Discussion {#s0035}
=============

The current study reports a family, which is very unusual from a clinical-genetic perspective. When referred, all members over two generations showed clinical symptoms that partially overlapped. As the pedigree was not readily compatible with a classical mode of inheritance ([Fig. 1](#f0005){ref-type="fig"}A), a non-genetic infectious etiology had been considered \[e.g. \[[@bb0030]\]\], but corresponding tests were negative. The presence of Parkinsonism in a first-degree relative may be considered suggestive of GD \[[@bb0035]\], but still represents a rather unspecific finding. The diagnosis of GD was ultimately reached at a specialized center, where appropriate biochemical testing and genetic follow-up were eventually initiated in all patients. The family thereby nicely exemplifies that, even in the presence of a positive family history, there are specific challenges for properly diagnosing GD \[[@bb0040]\].

The unusual clinical transmission pattern in this family may best be described as pseudodominant. This phenomenon refers to the observation of affected individuals in successive generations despite an autosomal recessive mode of inheritance; it is particularly common in populations with high carrier rates \[[@bb0045]\]. In this family, the presence of bi-allelic pathogenic variants in both parents (rather than in just one) and the distinctiveness of the variants adds further complexity.

All three *GBA* variants that were detected have been known as pathogenic mutations since the early days of GD genetics \[[@bb0050]\]. The variants are not only frequent in patients (HGMD), but also observed in heterozygosity in healthy individuals (gnomAD). To the best of our knowledge, however, combined occurrence in a single family is unprecedented. With the exception of c.1226G \> A, all variants may be pseudogene-derived \[[@bb0055]\]. The c.\[1265_1319del;1342G \> C\] allele, harboring two such variants *in cis*, is particularly suggestive in this respect.

The predicted consequences for the three pathogenic haplotypes vary. While c.\[1265_1319del;1342G \> C\] (p.Leu422Profs\*4) is a true loss-of-function allele, c.259C \> T (p.Arg87Trp) and c.1226A \> G (p.Asn409Ser) result in missense mutated proteins that may retain residual functionality. Moreover, c.1226A \> G (p.Asn409Ser) has been shown to represent a particularly mild mutation \[[@bb0060]\]. The resulting concept of variably pathogenic genotypes \[[@bb0065]\] is nicely supported by the presented family: individual I-4 carrying p.Asn409Ser in homozygosity has the overall mildest manifestation, while compound heterozygosity for p.Asn409Ser and the 'ordinary' missense variant p.Arg87Trp, for p.Asn409Ser and the truncating p.Leu422Profs\*4, and for p.Arg87Trp and p.Leu422Profs\*4 entail ever more severe phenotypes. This becomes particularly evident in the siblings in generation II: the manifestations in patients II-2 and II-3 represent a mild clinical picture (only spenomegaly) compared with that of patient II-1, who presented far more severely with splenomegaly, hepatomegaly, thrombocytopenia and bone pain ([Table 1](#t0005){ref-type="table"}).

Interestingly, the above genetic and clinical differences seem to also manifest at the metabolic level: Lyso-Gb1 values, covering more than one order of magnitude, nicely correlate with presumed pathogenicity of the genotypes and with clinical manifestation ([Table 1](#t0005){ref-type="table"}). This observation corroborates previous related claims \[[@bb0015]\]. Together with the accumulating evidence for Lyso-Gb1 to enable therapeutic monitoring in GD \[[@bb0020],[@bb0070]\], it also argues for a more widespread utilization of this biomarker, and for an extension of metabolic biomarker development to related genetic disorders \[[@bb0075]\].
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